#Global Trends – Page 12 – HEALTHCARE INSIGHTS

Key Development On September 8, 2026, biotechnology multinational Amgen (NASDAQ: AMGN) and biopharmaceutical leader AstraZeneca (LSE/Nasdaq: AZN) announced headline outcomes... Read more

Tag: #Global Trends

ENHERTU WINS ON DISEASE CONTROL, BUT SURVIVAL SIGNAL PUTS ITS FIRST-LINE AMBITION UNDER PRESSURE

GSK’S DRESDEN EXIT SIGNALS A SHIFT FROM LEGACY VACCINE CAPACITY TO NEXT-GENERATION PLATFORMS

MIFEPRISTONE AT THE INTERSECTION OF FDA AUTHORITY, TELEHEALTH AND STATE ABORTION BANS

ABBVIE’S LUNA WIN COULD OPEN A NEW CGRP FRONT IN MENSTRUAL MIGRAINE PREVENTION

ROIVANT’S MOSLICIGUAT PHASE 2 WIN COULD RESHAPE THE PH-ILD TREATMENT LANDSCAPE — AND VALIDATE A HIGH-VALUE BIOTECH ASSET STRATEGY

Biopharmaceutical R&D Infrastructure & Scientific Computing: Gilead Sciences Commissions 182,000-Sq-Ft Research Center at Foster City Campus – Core Milestone in $32 Billion Long-Term U.S. Innovation and Biomanufacturing Commitment

Thoracic Immuno-Oncology & Strategic Pipeline Recovery: Amgen’s Imdelltra® Plus AstraZeneca’s Imfinzi® Delivers Statistically Significant Overall Survival Benefit in Pivotal Phase 3 ES-SCLC Maintenance Trial

Reproductive Endocrinology & Gestational Pharmacovigilance: Danish Prospective Study Links Maternal Acetaminophen (Tylenol) Use During Pregnancy to Reduced Ovarian and Uterine Volume and Lower Follicular Reserve in Female Infants

Neuromuscular Oligonucleotide Therapeutics & Platform M&A Governance: Novartis’ Lead AOC Candidate Del-Desiran Misses Primary Endpoint in Pivotal Phase 3 HARBOR Trial for Myotonic Dystrophy Type 1 – Raising Scrutiny on $12 Billion Avidity Biosciences Acquisition

Facebook

Map

Online Members